A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine and 7-valent pneumococcal conjugate vaccine in Vaccines, Pneumococcal, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 46 sites in France. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-08-15.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine pediatric vaccines in France.
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
13-valent pneumococcal conjugate vaccine
Biological: 13-valent pneumococcal conjugate vaccine · Drug: Pentavac
7-valent pneumococcal conjugate vaccine
Biological: 7-valent pneumococcal conjugate vaccine · Drug: Pentavac
Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).
Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria, Tetanus, Hemophilus Influenza Type b (Hib), Poliomyelitis (Type 1, 2, 3), Pertussis Toxin (PT) and Filamentous Hemagglutinin (FHA) in 13vPnC Group Relative to 7vPnC Group
Percentage of participants achieving predefined antibody threshold levels ≥0.1 IU/mL for diphtheria, ≥0.1 IU/mL for tetanus, ≥ 0.15 μg/mL for Hib polyribosylribitol phosphate (PRP), antibody titer ≥1:8 for polio and ≥5 EU/mL for pertussis (PT and FHA) with the corresponding 95% CI for each concomitant antigen are presented.
Time frame: One Month After the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)
Geometric Mean Concentration (GMC) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) for Diphtheria Toxoid and Tetanus Toxoid in 13vPnC Group Relative to 7vPnC Group
Time frame: One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)
Geometric Mean Concentration (GMC) for Haemophilus Influenzae Type b (Hib) in 13vPnC Group Relative to 7vPnC Group
Time frame: One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)
Geometric Mean Concentration (GMC) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) for Poliomyelitis (Type 1, Type 2 and Type 3) in 13vPnC Group Relative to 7vPnC Group
Time frame: One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)
Geometric Mean Concentration (GMC) as Measured by ELISA for Pertussis Toxin (PT) and Pertussis Filamentous Hemagglutinin (FHA) in 13vPnC Group Relative to 7vPnC Group
Time frame: One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)
Percentage of Participants Achieving a Pneumococcal Antibody Level ≥0.35µg/mL (ELISA) After the 3-Dose Infant Series of 13vPnC
Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after the 3-Dose Infant Series (at 5 months of age)
Percentage of Participants Reporting Pre-Specified Local Reactions
Local reactions were collected using an electronic diary. Tenderness (Tender)was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (Sev) (\>7.0 cm). Participants may be represented in more than 1 category.
Time frame: During the 4-day period after each dose
Percentage of Participants Reporting Pre-Specified Systemic Events
Systemic events (fever \[fv\] ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased \[decr\] appetite, irritability, increased \[incr\] sleep, decreased sleep, hives, use of medication \[med\] to treat symptoms \[sx\], and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: During the 4-day period after each dose
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the 3-Dose Infant Series of 13vPnC
Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated.
Time frame: One month after the 3-Dose Infant Series (at 5 months of age)
Percentage of Participants Achieving a Pneumococcal Antibody Level ≥0.35µg/mL (ELISA) After the Toddler Dose in the 13vPnC/13vPnC, 7vPnC/7vPnC and 7vPnC/13vPnC Groups
Percentages of participants achieving World health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after the toddler dose (at 13 months of age)
Pneumococcal Geometric Mean Concentration (GMC) Before and After the Toddler Dose in the 13vPnC/13vPnC, 7vPnC/7vPnC and 7vPnC/13vPnC Groups
Antibody GMC as measured by ELISA for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after the Toddler Dose (at 13 months of age)
Percentage of Participants Achieving Antibody Titer ≥1:8 After the Toddler Dose in 13vPnC/13vPnC and 7vPnC/13vPnC Groups
Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after the toddler dose (at 13 months of age)
Geometric Mean Titer (GMT) in 13vPnC/13vPnC and 7vPnC/13vPnC Groups After the Toddler Dose
GMT as measured by opsonophagocytic activity assay (OPA) for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after the toddler dose (at 13 months of age)
Participants were recruited in France from October 2006 to July 2007.
| Milestone | 13vPnC/13vPnC Vaccine | 7vPnC/7vPnC Vaccine | 7vPnC/13vPnC Vaccine |
|---|---|---|---|
| Started | 304 | 309 | 0 |
| Vaccinated dose 1 | 302 | 309 | 0 |
| Vaccinated dose 2 | 295 | 304 | 0 |
| Vaccinated dose 3 | 291 | 302 | 0 |
| Completed | 290 | 299 | 0 |
| Not completed | 14 | 10 | 0 |
| Withdrew: Withdrawal by subject | 8 | 6 | 0 |
| Withdrew: Protocol violation | 4 | 3 | 0 |
| Withdrew: Failed to return | 1 | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Milestone | 13vPnC/13vPnC Vaccine | 7vPnC/7vPnC Vaccine | 7vPnC/13vPnC Vaccine |
|---|---|---|---|
| Started | 290 | 299 | 0 |
| Completed | 273 | 289 | 0 |
| Not completed | 17 | 10 | 0 |
| Withdrew: Withdrawal by subject | 8 | 4 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 |
| Withdrew: Failed to return | 5 | 5 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Milestone | 13vPnC/13vPnC Vaccine | 7vPnC/7vPnC Vaccine | 7vPnC/13vPnC Vaccine |
|---|---|---|---|
| Started | 273 | 152 | 137 |
| Completed | 268 | 151 | 137 |
| Not completed | 5 | 1 | 0 |
| Withdrew: Protocol violation | 2 | 1 | 0 |
| Withdrew: Failed to return | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 0 |
Percentage of participants achieving predefined antibody threshold levels ≥0.1 IU/mL for diphtheria, ≥0.1 IU/mL for tetanus, ≥ 0.15 μg/mL for Hib polyribosylribitol phosphate (PRP), antibody titer ≥1:8 for polio and ≥5 EU/mL for pertussis (PT and FHA) with the corresponding 95% CI for each concomitant antigen are presented.
| percentage of participants | 13vPnC After the Infant Series | 7vPnC After the Infant Series | 13vPnC After the Toddler Dose | 7vPnC After the Toddler Dose |
|---|---|---|---|---|
| Pertussis - PT Infant ≥5 Toddler 5 (EU/mL) | 100.0 (98.6 to 100.0) | 100.0 (98.6 to 100.0) | 100.0 (98.5 to 100.0) | 100.0 (97.3 to 100.0) |
| Pertussis - PT Infant ≥26 Toddler 17 (EU/mL) | 94.3 (90.8 to 96.8) | 95.0 (91.7 to 97.3) | 98.3 (95.8 to 99.5) | 96.2 (91.4 to 98.8) |
| Pertussis - FHA Infant ≥5 Toddler 5 (EU/mL) | 100.0 (98.6 to 100.0) | 100.0 (98.6 to 100.0) | 100.0 (98.5 to 100.0) | 100.0 (97.3 to 100.0) |
| Pertussis - FHA Infant ≥7.82 Toddler 7.82 (EU/mL) | 100.0 (98.6 to 100.0) | 100.0 (98.6 to 100.0) | 100.0 (98.5 to 100.0) | 100.0 (97.3 to 100.0) |
| Pertussis - FHA Infant ≥36.00 Toddler 75 (EU/mL) | 93.5 (89.9 to 96.2) | 95.8 (92.6 to 97.9) | 92.5 (88.4 to 95.5) | 95.5 (90.4 to 98.3) |
| Diphtheria 0.1 (IU/mL) | 76.5 (70.9 to 81.5) | 84.6 (79.6 to 88.7) | 99.2 (97.0 to 99.9) | 100 (97.3 to 100.0) |
| Diphtheria 0.01 (IU/mL) | 100.0 (98.6 to 100.0) | 100.0 (98.6 to 100.0) | 100.0 (98.5 to 100.0) | 100.0 (97.3 to 100.0) |
| Tetanus 0.1 (IU/mL) | 84.9 (80.0 to 89.1) | 82.2 (76.9 to 86.7) | 96.2 (93.0 to 98.3) | 98.5 (94.7 to 99.8) |
| Tetanus 0.01 (IU/mL) | 100.0 (98.6 to 100.0) | 100.0 (98.6 to 100.0) | 100.0 (98.5 to 100.0) | 100.0 (97.3 to 100.0) |
| Polio Type 1 (1:8) | 88.8 (84.3 to 92.3) | 91.0 (86.8 to 94.2) | 97.9 (95.2 to 99.3) | 98.4 (94.5 to 99.8) |
| Polio Type 2 (1:8) | 77.7 (72.1 to 82.6) | 82.0 (76.8 to 86.5) | 98.7 (96.4 to 99.7) | 99.2 (95.8 to 100.0) |
| Polio Type 3 (1:8) | 92.6 (88.7 to 95.5) | 93.0 (89.1 to 95.8) | 99.2 (97.0 to 99.9) | 100.0 (97.2 to 100.0) |
| Hib (PRP) 0.15 (μg/mL) | 95.5 (92.1 to 97.7) | 94.6 (91.0 to 97.1) | 100.0 (98.5 to 100.0) | 100.0 (97.2 to 100.0) |
| Hib (PRP) 1.0 (μg/mL) | 58.6 (52.1 to 64.9) | 63.1 (56.6 to 69.2) | 97.9 (95.2 to 99.3) | 97.7 (93.5 to 99.5) |
Percentages of participants achieving World health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| percentage of participants | 13vPnC Infant Series / 13vPnC Toddler Dose | 7vPnC Infant Series / 7vPnC Toddler Dose | 7vPnC Infant Series / 13vPnC Toddler Dose |
|---|---|---|---|
| Common Serotypes - Serotype 4 (n=233,126,111) | 100.0 (98.4 to 100.0) | 100.0 (97.1 to 100.0) | 99.1 (95.1 to 100.0) |
| Common Serotypes - Serotype 6B (n=233,126,108) | 99.6 (97.6 to 100.0) | 99.2 (95.7 to 100.0) | 98.1 (93.5 to 99.8) |
| Common Serotypes - Serotype 9V (n=232,124,109) | 100.0 (98.4 to 100.0) | 100.0 (97.1 to 100.0) | 100.0 (96.7 to 100.0) |
| Common Serotypes - Serotype 14 (n=233,135,111) | 99.6 (97.6 to 100.0) | 100.0 (97.1 to 100.0) | 99.1 (95.1 to 100.0) |
| Common Serotypes - Serotype 18C (n=230,125,113) | 99.6 (97.6 to 100.0) | 99.2 (95.6 to 100.0) | 98.2 (93.8 to 99.8) |
| Common Serotypes - Serotype 19F (n=233,126,112) | 97.9 (95.1 to 99.3) | 97.6 (93.2 to 99.5) | 97.3 (92.4 to 99.4) |
| Common Serotypes - Serotype 23F (n=232,123,111) | 99.6 (97.6 to 100.0) | 99.2 (95.6 to 100.0) | 99.1 (95.1 to 100.0) |
| Additional Serotypes - Serotype 1 (n=233,119,112) | 100.0 (98.4 to 100.0) | 0.8 (0.0 to 4.6) | 95.5 (89.9 to 98.5) |
| Additional Serotypes - Serotype 3 (n=233,124,113) | 94.8 (91.2 to 97.3) | 13.7 (8.2 to 21.0) | 93.8 (87.7 to 97.5) |
| Additional Serotypes - Serotype 5 (n=236,111,111) | 100.0 (98.4 to 100.0) | 73.0 (63.7 to 81.0) | 90.1 (83.0 to 94.9) |
| Additional Serotypes - Serotype 6A (n=235,124,109) | 100.0 (98.4 to 100.0) | 89.5 (82.7 to 94.3) | 89.9 (82.7 to 94.9) |
| Additional Serotypes - Serotype 7F (n=234,124,110) | 100.0 (98.4 to 100.0) | 7.3 (3.4 to 13.3) | 100.0 (96.7 to 100.0) |
| Additional Serotypes - Serotype 19A(n=233,127,112) | 100.0 (98.4 to 100.0) | 100.0 (97.1 to 100.0) | 100.0 (96.8 to 100.0) |
Antibody GMC as measured by ELISA for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| μg/mL | 13vPnC/13vPnC Before Toddler Dose | 13vPnC/13vPnC After Toddler Dose | 7vPnC/7vPnC Before Toddler Dose | 7vPnC/7vPnC After Toddler Dose | 7vPnC/13vPnC Before Toddler Dose | 7vPnC/13vPnC After Toddler Dose |
|---|---|---|---|---|---|---|
| Common - Serotype 4 (n=239,233,131,126,118,111) | 0.3 (0.3 to 0.3) | 4.2 (3.8 to 4.7) | 0.5 (0.4 to 0.5) | 4.8 (4.2 to 5.6) | 0.5 (0.4 to 0.5) | 4.0 (3.4 to 4.8) |
| Common - Serotype 6B (n=235,233,131,126,115,108) | 1.0 (0.9 to 1.1) | 9.0 (8.0 to 10.1) | 1.1 (0.9 to 1.3) | 9.6 (8.3 to 11.2) | 0.9 (0.8 to 1.1) | 10.3 (8.2 to 13.0) |
| Common - Serotype 9V (n=239,232,131,124,118,109) | 0.4 (0.4 to 0.5) | 2.3 (2.3 to 2.8) | 0.5 (0.5 to 0.6) | 3.2 (2.8 to 3.7) | 0.4 (0.4 to 0.5) | 2.3 (2.0 to 2.6) |
| Common - Serotype 14 (n=238,233,131,125,118,111) | 2.0 (1.8 to 2.3) | 9.5 (8.5 to 10.6) | 2.4 (2.1 to 2.9) | 10.8 (9.4 to 12.5) | 2.4 (2.0 to 3.0) | 7.8 (6.6 to 9.3) |
| Common - Serotype 18C (n=239,230,131,125,118,113) | 0.3 (0.3 to 0.3) | 2.3 (2.1 to 2.5) | 0.3 (0.3 to 0.4) | 2.8 (2.5 to 3.2) | 0.3 (0.3 to 0.4) | 2.4 (2.0 to 2.9) |
| Common - Serotype 19F (n=239,233,130,126,118,112) | 0.7 (0.6 to 0.7) | 5.2 (4.5 to 6.0) | 0.7 (0.6 to 0.9) | 4.1 (3.4 to 5.0) | 0.6 (0.5 to 0.7) | 3.7 (3.0 to 4.6) |
| Common - Serotype 23F (n=237,232,130,123,118,111) | 0.3 (0.2 to 0.3) | 3.0 (2.7 to 3.4) | 0.3 (0.3 to 0.4) | 3.7 (3.1 to 4.3) | 0.3 (0.2 to 0.4) | 3.1 (2.6 to 3.7) |
| Additional-Serotype 1 (n=239,233,128,119,116,112) | 0.4 (0.4 to 0.5) | 4.1 (3.7 to 4.5) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) | 1.8 (1.5 to 2.2) |
| Additional-Serotype 3 (n=232,233,128,124,115,113) | 0.2 (0.2 to 0.2) | 1.0 (0.9 to 1.1) | 0.1 (0.1 to 0.1) | 0.1 (0.1 to 0.1) | 0.1 (0.1 to 0.1) | 1.3 (1.1 to 1.5) |
| Additional-Serotype 5 (n=236,236,128,124,115,113) | 0.8 (0.7 to 0.9) | 3.3 (3.0 to 3.7) | 0.4 (0.4 to 0.5) | 0.5 (0.4 to 0.6) | 0.4 (0.4 to 0.5) | 1.1 (1.0 to 1.3) |
| Additional-Serotype 6A (n=238,235,122,124,116,109) | 0.9 (0.8 to 1.0) | 6.1 (5.5 to 6.8) | 0.4 (0.3 to 0.5) | 1.5 (1.3 to 1.9) | 0.4 (0.3 to 0.4) | 2.6 (2.0 to 3.4) |
| Additional-Serotype 7F (n=239,234,131,124,117,110) | 0.8 (0.7 to 0.9) | 4.5 (4.1 to 5.0) | 0.1 (0.0 to 0.1) | 0.1 (0.0 to 0.1) | 0.1 (0.1 to 0.1) | 3.7 (3.2 to 4.3) |
| Additional-Serotype 19A(n=237,233,131,127,117,112) | 1.5 (1.3 to 1.7) | 9.5 (8.5 to 10.6) | 1.1 (0.9 to 1.3) | 4.0 (3.5 to 4.5) | 0.9 (0.7 to 1.1) | 5.3 (4.6 to 6.2) |
Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| Percentage of Participants | 13vPnC/13vPnC After Toddler Dose | 7vPnC/13vPnC After Toddler Dose |
|---|---|---|
| Additional Serotypes - Serotype 1 | 100.0 (95.9 to 100.0) | 98.9 (94.0 to 100.0) |
| Additional Serotypes - Serotype 3 | 100.0 (95.9 to 100.0) | 97.8 (92.2 to 99.7) |
| Additional Serotypes - Serotype 5 | 100.0 (95.9 to 100.0) | 97.8 (92.2 to 99.7) |
| Additional Serotypes - Serotype 6A | 100.0 (95.8 to 100.0) | 98.9 (94.0 to 100.0) |
| Additional Serotypes - Serotype 7F | 100.0 (95.8 to 100.0) | 100.0 (95.9 to 100.0) |
| Additional Serotypes - Serotype 19A | 98.8 (93.7 to 100.0) | 97.8 (92.2 to 99.7) |
GMT as measured by opsonophagocytic activity assay (OPA) for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| titer | 13vPnC/13vPnC After Toddler Dose | 7vPnC/13vPnC After Toddler Dose |
|---|---|---|
| Additional Serotypes - Serotype 1 | 126.00 (99.87 to 158.97) | 61.58 (47.72 to 79.47) |
| Additional Serotypes - Serotype 3 | 345.33 (296.06 to 402.80) | 428.88 (346.69 to 530.56) |
| Additional Serotypes - Serotype 5 | 244.18 (200.14 to 297.92) | 130.99 (103.68 to 165.50) |
| Additional Serotypes - Serotype 6A | 1346.83 (1143.98 to 1585.65) | 891.44 (694.76 to 1143.81) |
| Additional Serotypes - Serotype 7F | 8126.24 (6657.36 to 9919.21) | 17034.59 (14316.59 to 20268.60) |
| Additional Serotypes - Serotype 19A | 804.06 (615.90 to 1049.71) | 1072.43 (799.06 to 1439.32) |
| IU/mL | 13vPnC After the Infant Series | 7vPnC After the Infant Series | 13vPnC After the Toddler Dose | 7vPnC After the Toddler Dose |
|---|---|---|---|---|
| Diphtheria | 0.19 (0.17 to 0.21) | 0.24 (0.22 to 0.27) | 2.09 (1.87 to 2.34) | 2.60 (2.26 to 2.99) |
| Tetanus | 0.20 (0.18 to 0.22) | 0.21 (0.19 to 0.23) | 1.08 (0.94 to 1.24) | 1.25 (1.05 to 1.47) |
| μg/mL | 13vPnC After the Infant Series | 7vPnC After the Infant Series | 13vPnC After the Toddler Dose | 7vPnC After the Toddler Dose |
|---|---|---|---|---|
| Geometric Mean Concentration (GMC) for Haemophilus Influenzae Type b (Hib) in 13vPnC Group Relative to 7vPnC Group | 1.28 (1.10 to 1.49) | 1.40 (1.19 to 1.64) | 12.15 (10.54 to 14.00) | 11.68 (9.66 to 14.13) |
| titer | 13vPnC After the Infant Series | 7vPnC After the Infant Series | 13vPnC After the Toddler Dose | 7vPnC After the Toddler Dose |
|---|---|---|---|---|
| Polio Type 1 | 24.99 (21.37 to 29.23) | 28.33 (24.40 to 32.89) | 253.05 (207.15 to 309.11) | 250.56 (193.17 to 324.99) |
| Polio Type 2 | 17.75 (15.07 to 20.92) | 21.55 (18.43 to 25.20) | 408.34 (338.94 to 491.95) | 415.20 (325.57 to 529.52) |
| Polio Type 3 | 41.08 (34.08 to 49.52) | 52.95 (43.26 to 64.82) | 536.32 (436.46 to 659.02) | 638.18 (501.50 to 812.13) |
| EU/mL | 13vPnC After the Infant Series | 7vPnC After the Infant Series | 13vPnC After the Toddler Dose | 7vPnC After the Toddler Dose |
|---|---|---|---|---|
| Pertussis - FHA | 97.12 (89.84 to 104.98) | 111.23 (102.80 to 120.35) | 204.28 (185.65 to 224.79) | 241.08 (210.92 to 275.55) |
| Pertussis - PT | 62.94 (58.80 to 67.38) | 68.20 (63.60 to 73.14) | 61.09 (56.19 to 66.40) | 61.70 (54.55 to 69.78) |
Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| percentage of participants | 13vPnC |
|---|---|
| Common Serotypes - Serotype 4 (n=244) | 91.4 (87.1 to 94.6) |
| Common Serotypes - Serotype 6B (n=241) | 72.6 (66.5 to 78.1) |
| Common Serotypes - Serotype 9V (n=238) | 92.9 (88.8 to 95.8) |
| Common Serotypes - Serotype 14 (n=236) | 94.9 (91.3 to 97.3) |
| Common Serotypes - Serotype 18C (n=242) | 90.5 (86.1 to 93.9) |
| Common Serotypes - Serotype 19F (n=241) | 97.9 (95.2 to 99.3) |
| Common Serotypes - Serotype 23F (n=244) | 82.8 (77.5 to 87.3) |
| Additional Serotypes - Serotype 1 (n=240) | 90.8 (86.5 to 94.2) |
| Additional Serotypes - Serotype 3 (n=242) | 96.3 (93.1 to 98.3) |
| Additional Serotypes - Serotype 5 (n=243) | 84.0 (78.7 to 88.3) |
| Additional Serotypes - Serotype 6A (n=243) | 85.6 (80.5 to 89.8) |
| Additional Serotypes - Serotype 7F (n=238) | 97.5 (94.6 to 99.1) |
| Additional Serotypes - Serotype 19A (n=244) | 97.5 (94.7 to 99.1) |
Local reactions were collected using an electronic diary. Tenderness (Tender)was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (Sev) (\>7.0 cm). Participants may be represented in more than 1 category.
| Percentage of Participants | 13vPnC Dose 1 | 7vPnC Dose 1 | 13vPnC Dose 2 | 7vPnC Dose 2 | 13vPnC Dose 3 | 7vPnC Dose 3 | 13vPnC/13vPnC Toddler Dose | 7vPnC/7vPnC Toddler Dose | 7vPnC/13vPnC Toddler Dose |
|---|---|---|---|---|---|---|---|---|---|
| Tender-Any (n=256,257,223,225,210,206,189,96,89) | 38.3 | 38.5 | 33.2 | 42.2 | 36.2 | 32.0 | 50.3 | 44.8 | 64.0 |
| Tender-Sig (n=237,245,203,208,188,193,155,86,75) | 5.5 | 4.9 | 5.4 | 6.7 | 3.7 | 3.1 | 5.2 | 4.7 | 8.0 |
| Swelling-Any (n=254,256,226,235,217,219,185,99,97) | 41.3 | 38.7 | 50.0 | 54.5 | 48.4 | 51.1 | 53.5 | 57.6 | 59.8 |
| Swelling-Mild(n=249,255,223,232,213,214,181,99,95) | 36.9 | 35.7 | 46.6 | 51.3 | 44.6 | 45.8 | 48.1 | 55.6 | 57.9 |
| Swelling-Mod (n=243,246,207,208,193,194,159,88,82) | 14.4 | 9.3 | 14.0 | 14.4 | 14.0 | 16.0 | 19.5 | 15.9 | 20.7 |
| Swelling-Sev (n=235,244,199,203,184,188,152,87,73) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 | 0.0 |
| Redness-Any (n=256,260,236,241,226,223,187,106,99) | 44.5 | 46.9 | 53.4 | 58.1 | 55.8 | 59.2 | 66.8 | 60.4 | 63.6 |
| Redness-Mild(n=252,259,234,240,223,221,180,106,95) | 40.9 | 45.6 | 50.9 | 56.7 | 52.5 | 55.7 | 60.0 | 54.7 | 60.0 |
| Redness-Mod (n=241,245,205,206,190,192,165,87,79) | 9.5 | 3.7 | 7.3 | 6.8 | 8.9 | 12.5 | 24.2 | 18.4 | 20.3 |
| Redness-Sev (n=234,244,199,203,184,188,152,86,73) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 | 0.0 |
Systemic events (fever \[fv\] ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased \[decr\] appetite, irritability, increased \[incr\] sleep, decreased sleep, hives, use of medication \[med\] to treat symptoms \[sx\], and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.
| Percentage of Participants | 13vPnC Dose 1 | 7vPnC Dose 1 | 13vPnC Dose 2 | 7vPnC Dose 2 | 13vPnC Dose 3 | 7vPnC Dose 3 | 13vPnC/13vPnC Toddler Dose | 7vPnC/7vPnC Toddler Dose | 7vPnC/13vPnC Toddler Dose |
|---|---|---|---|---|---|---|---|---|---|
| Fv≥38°C,≤39°C(n=244,250,212,217,201,208,174,99,83) | 13.5 | 10.0 | 19.8 | 25.3 | 26.9 | 27.9 | 36.8 | 41.4 | 42.2 |
| Fv>39°C,≤40°C(n=238,245,201,205,184,191,153,89,73) | 0.8 | 0.4 | 1.0 | 2.4 | 0.5 | 1.6 | 4.6 | 2.2 | 4.1 |
| Fv >40°C (n=238,245,200,205,184,190,153,88,73) | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 0.0 | 0.7 | 0.0 | 0.0 |
| Decr appetite(n=243,251,211,218,194,199,167,96,83) | 24.7 | 23.1 | 18.5 | 26.1 | 23.2 | 21.1 | 29.3 | 34.4 | 31.3 |
| Irritability (n=261,265,232,238,217,211,178,99,91) | 54.4 | 52.5 | 48.3 | 49.6 | 41.9 | 40.3 | 50.6 | 46.5 | 50.5 |
| Incr sleep (n=256,259,215,227,194,204,163,92,81) | 34.0 | 41.3 | 28.4 | 32.2 | 23.7 | 28.4 | 21.5 | 23.9 | 23.5 |
| Decr sleep (n=246,253,,215,218,203,196,168,93,81) | 28.0 | 20.6 | 26.5 | 27.1 | 25.1 | 20.9 | 26.2 | 22.6 | 30.9 |
| Med-treat sx(n=248,259,224,227,202,214,180,100,89) | 29.0 | 32.8 | 38.4 | 44.5 | 36.1 | 42.1 | 47.8 | 54.0 | 55.1 |
| Med-prevent sx(n=252,260,221,236,201,213,181,99,85 | 34.5 | 34.6 | 36.7 | 40.3 | 28.4 | 37.6 | 38.7 | 44.4 | 40.0 |
Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated.
| μg/mL | 13vPnC |
|---|---|
| Common Serotypes - Serotype 4 (n=244) | 1.29 (1.14 to 1.46) |
| Common Serotypes - Serotype 6B (n=241) | 0.74 (0.62 to 0.89) |
| Common Serotypes - Serotype 9V (n=238) | 1.15 (1.03 to 1.28) |
| Common Serotypes - Serotype 14 (n=236) | 2.74 (2.38 to 3.16) |
| Common Serotypes - Serotype 18C (n=242) | 1.42 (1.26 to 1.60) |
| Common Serotypes - Serotype 19F (n=241) | 1.55 (1.42 to 1.70) |
| Common Serotypes - Serotype 23F (n=244) | 0.92 (0.80 to 1.06) |
| Additional Serotypes - Serotype 1 (n=240) | 1.21 (1.07 to 1.38) |
| Additional Serotypes - Serotype 3 (n=242) | 1.25 (1.13 to 1.37) |
| Additional Serotypes - Serotype 5 (n=243) | 0.93 (0.82 to 1.06) |
| Additional Serotypes - Serotype 6A (n=243) | 0.94 (0.82 to 1.06) |
| Additional Serotypes - Serotype 7F (n=238) | 1.93 (1.73 to 2.15) |
| Additional Serotypes - Serotype 19A (n=244) | 2.10 (1.87 to 2.35) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC Infant Series | — | 5/304 (1.6%) | 142/304 (46.7%) |
| 7vPnC Infant Series | — | 5/309 (1.6%) | 162/309 (52.4%) |
| 13vPnC Post-Infant Series | — | 8/290 (2.8%) | 12/290 (4.1%) |
| 7vPnC Post-Infant Series | — | 5/299 (1.7%) | 11/299 (3.7%) |
| 13vPnC/13vPnC Toddler Dose | — | 2/273 (0.7%) | 125/272 (46%) |
| 7vPnC/7vPnC Toddler Dose | — | 0/152 (0%) | 64/152 (42.1%) |
| 7vPnC/ 13vPnC Toddler Dose | — | 2/134 (1.5%) | 63/137 (46%) |
| 13vPnC / 13vPnC 6-Month Follow-up | — | 6/267 (2.2%) | 2/267 (0.7%) |
| 7vPnC / 7vPnC 6-Month Follow-up | — | 1/150 (0.7%) | 2/150 (1.3%) |
| 7vPnC / 13vPnC 6-Month Follow-up | — | 0/133 (0%) | 2/133 (1.5%) |
| Event | 13vPnC Infant Series | 7vPnC Infant Series | 13vPnC Post-Infant Series | 7vPnC Post-Infant Series | 13vPnC/13vPnC Toddler Dose | 7vPnC/7vPnC Toddler Dose | 7vPnC/ 13vPnC Toddler Dose | 13vPnC / 13vPnC 6-Month Follow-up | 7vPnC / 7vPnC 6-Month Follow-up | 7vPnC / 13vPnC 6-Month Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|
| GastroenteritisInfections and infestations | 1/304 | 1/309 | 2/290 | 1/299 | 0/273 | 0/152 | 1/134 | 2/267 | 0/150 | 0/133 |
| BronchiolitisInfections and infestations | 2/304 | 1/309 | 1/290 | 0/299 | 0/273 | 0/152 | 1/134 | 0/267 | 1/150 | 0/133 |
| Lung disorderRespiratory, thoracic and mediastinal disorders | 0/304 | 0/309 | 0/290 | 0/299 | 0/273 | 0/152 | 1/134 | 0/267 | 0/150 | 0/133 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/304 | 0/309 | 1/290 | 0/299 | 0/273 | 0/152 | 0/134 | 0/267 | 1/150 | 0/133 |
| DehydrationMetabolism and nutrition disorders | 0/304 | 0/309 | 0/290 | 0/299 | 0/273 | 0/152 | 0/134 | 1/267 | 0/150 | 0/133 |
| Otitis media acuteInfections and infestations | 0/304 | 0/309 | 0/290 | 0/299 | 0/273 | 0/152 | 0/134 | 1/267 | 0/150 | 0/133 |
| PneumoniaInfections and infestations | 0/304 | 0/309 | 0/290 | 0/299 | 0/273 | 0/152 | 0/134 | 1/267 | 0/150 | 0/133 |
| PyelonephritisInfections and infestations | 0/304 | 1/309 | 0/290 | 1/299 | 0/273 | 0/152 | 0/134 | 1/267 | 0/150 | 0/133 |
| Gastroenteritis bacterialInfections and infestations | 0/304 | 0/309 | 0/290 | 0/299 | 1/273 | 0/152 | 0/134 | 0/267 | 0/150 | 0/133 |
| HypotoniaNervous system disorders | 0/304 | 0/309 | 0/290 | 0/299 | 1/273 | 0/152 | 0/134 | 0/267 | 0/150 | 0/133 |
| Event | 13vPnC Infant Series | 7vPnC Infant Series | 13vPnC Post-Infant Series | 7vPnC Post-Infant Series | 13vPnC/13vPnC Toddler Dose | 7vPnC/7vPnC Toddler Dose | 7vPnC/ 13vPnC Toddler Dose | 13vPnC / 13vPnC 6-Month Follow-up | 7vPnC / 7vPnC 6-Month Follow-up | 7vPnC / 13vPnC 6-Month Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|
| Erythema (Any)Skin and subcutaneous tissue disorders | 114/256 | 122/260 | — | — | 125/187 | 64/106 | 63/99 | — | — | — |
| Tenderness (Any)Skin and subcutaneous tissue disorders | 98/256 | 99/257 | — | — | 95/189 | 43/96 | 57/89 | — | — | — |
| Erythema (Mild)Skin and subcutaneous tissue disorders | 103/252 | 118/259 | — | — | 108/180 | 58/106 | 57/95 | — | — | — |
| Induration (Any)Skin and subcutaneous tissue disorders | 105/254 | 99/256 | — | — | 99/185 | 57/99 | 58/97 | — | — | — |
| Erythema (Any)Skin and subcutaneous tissue disorders | 126/226 | 132/223 | — | — | — | — | — | — | — | 0/133 |
| Erythema (Any)Skin and subcutaneous tissue disorders | 126/236 | 140/241 | — | — | — | — | — | — | — | — |
| Induration (Mild)Skin and subcutaneous tissue disorders | 92/249 | 91/255 | — | — | 87/181 | 55/99 | 55/95 | — | — | — |
| Erythema (Mild)Skin and subcutaneous tissue disorders | 119/234 | 136/240 | — | — | — | — | — | — | — | — |
| Erythema (Mild)Skin and subcutaneous tissue disorders | 117/223 | 123/221 | — | — | — | — | — | — | — | — |
| Induration (Any)Skin and subcutaneous tissue disorders | 113/226 | 128/235 | — | — | — | — | — | — | — | — |
| Age Continuous(months) | 13vPnC/13vPnC Vaccine | 7vPnC/7vPnC Vaccine | Total |
|---|---|---|---|
| Mean | 2.1 ± 0.5 | 2.1 ± 0.5 | 2.1 ± 0.5 |
| Sex: Female, Male(Participants) | 13vPnC/13vPnC Vaccine | 7vPnC/7vPnC Vaccine | Total |
|---|---|---|---|
| Female | 169 | 164 | 333 |
| Male | 135 | 145 | 280 |
The record gives a start of Oct 2006, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 3 years 9 months after primary completion. A results delay was requested in Feb 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Wyeth is now a wholly owned subsidiary of Pfizer →